Compare QMCO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | OVID |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 117.5M |
| IPO Year | N/A | 2017 |
| Metric | QMCO | OVID |
|---|---|---|
| Price | $6.14 | $1.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $16.50 | $3.50 |
| AVG Volume (30 Days) | 567.7K | ★ 1.6M |
| Earning Date | 02-06-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,949,000.00 | $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $6.03 | $0.24 |
| 52 Week High | $25.46 | $2.01 |
| Indicator | QMCO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 45.09 |
| Support Level | $6.68 | $1.50 |
| Resistance Level | $7.10 | $1.61 |
| Average True Range (ATR) | 0.44 | 0.11 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 9.30 | 23.08 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.